All unexpired albuterol sulfate inhalation aerosol manufactured by Catalent Pharma Solutions for Perrigo Pharmaceutical Company is being recalled due to a possible device malfunction. Specifically, some of the inhalers may not dispense the medication due to a clogging issue.

Albuterol sulfate inhalation aerosol is indicated for the treatment or prevention of bronchospasm with reversible obstructive airway disease and for the prevention of exercise-induced bronchospasm. To date, Perrigo has received several thousand complaints related to their product. As of August 21, 2020, production and distribution of the albuterol sulfate inhaler was halted; the malfunction is currently being investigated.  

At this time, the FDA is advising patients to continue to use their inhaler, as needed and as directed, but to also have extra inhalers or an alternative treatment available in case of malfunction. Some of these recalled inhalers were found to stop working after several uses.

Related Articles

Health care professionals and patients can report adverse events associated with these products to the FDA’s MedWatch Program.

For more information visit


FDA alerts of Perrigo’s voluntary albuterol inhaler recall. Accessed September 22, 2020.